STAB

Statera Biopharma Inc

STAB, USA

Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company is developing therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn's disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401), and COVID-19 (STAT-205), as well as fibromyalgia and multiple sclerosis. The company was formerly known as Cytocom, Inc. and changed its name to Statera Biopharma, Inc. in September 2021. Statera Biopharma, Inc. is based in Fort Collins, Colorado. Statera Biopharma, Inc. is a subsidiary of Biostax Corp.

https://www.staterabiopharma.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
STAB
stock
STAB

Statera Biopharma (NASDAQ:STAB) vs. Orgenesis (NASDAQ:ORGS) Financial Contrast Defense World

Read more →
STAB
stock
STAB

BHP walks away from last stab at Anglo American takeover Reuters

Read more →

Showing 2 of 10

Finn Analysis

(Last Updated 2022-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

-0.00

Low 1

High 3

Return on Equity (ROE)

-

Very High

50.38 %

Low 5%

High 25%

Return on Assets (ROA)

-

Very Low

-40.47 %

Low 2%

High 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-120.51 %

Low 5%

High 15%

Investors

* Institutions hold a combined 0.30% of the total shares of Statera Biopharma Inc

1.

Acadian Asset Management LLC

(0.2966%)

since

2023/03/31

2.

TUCKER ASSET MANAGEMENT LLC

(0.0014%)

since

2023/03/31

3.

Royal Bank of Canada

(0.0003%)

since

2022/12/31

4.

CWM, LLC duplicate

(0.0002%)

since

2022/12/31

5.

IFP Advisors, LLC

(0.0001%)

since

2023/03/31

6.

UMB Bank NA

(0%)

since

2023/03/31

7.

State Street Corporation

(0%)

since

2023/03/31

9.

Wells Fargo & Co

(0%)

since

2023/03/31

10.

Tower Research Capital LLC

(0%)

since

2023/03/31

11.

Sandhill Capital Partners LLC

(0%)

since

2022/12/31

12.

Northern Trust Corp

(0%)

since

2023/03/31

13.

Archer Investment Corporation

(0%)

since

2023/03/31

14.

CI Private Wealth LLC

(0%)

since

2023/03/31

15.

Millennium Management LLC

(0%)

since

2023/03/31

17.

Ergoteles LLC

(0%)

since

2023/03/31

18.

Two Sigma Investments LLC

(0%)

since

2022/12/31

19.

Virtu Financial LLC

(0%)

since

2022/12/31

20.

Advisor Group Holdings, Inc.

(0%)

since

2023/03/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

EPS Estimate

Latest Release

Date

2024-09-30

EPS Actual

0

EPS Estimate

0

EPS Difference

0

Surprise Percent

null%

Investing Fit Scorecard

(Last Updated 2022-09-30)

Deep Value
Weak Deep Value(2.5)
Defensive
Moderately Defensive(5.5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(5.8)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(2)
Momentum
Moderate Momentum(4)
Net Net
Not Undervalued (Net-Net)(2)
Quality
Low Quality Business(3)
Value
Overpriced(3)

Income Statement

(Last Updated 2022-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2022-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2022-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.